128 related articles for article (PubMed ID: 8202820)
1. [Gonadotropin-releasing hormone analogues in the treatment of metastatic breast carcinoma].
Nesković-Konstantinović Z; Radulović S; Vuletić L
Srp Arh Celok Lek; 1993; 121(1-2):33-5. PubMed ID: 8202820
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone releasing hormone analogues for contraception.
Nillius SJ
Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
4. New approaches to the therapy of various tumors based on peptide analogues.
Schally AV
Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
[TBL] [Abstract][Full Text] [Related]
5. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
Schally AV; Redding TW; Comaru-Schally AM
Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
[TBL] [Abstract][Full Text] [Related]
6. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
[TBL] [Abstract][Full Text] [Related]
8. [History of clinical studies on hypothalamic hormone analogs in Mexico].
Schally AV; González Bárcena D
Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
[TBL] [Abstract][Full Text] [Related]
9. LH-RH analogues: I. Their impact on reproductive medicine.
Schally AV
Gynecol Endocrinol; 1999 Dec; 13(6):401-9. PubMed ID: 10685334
[TBL] [Abstract][Full Text] [Related]
10. Clinical uses of gonadotropin-releasing hormone analogues.
Casper RF
CMAJ; 1991 Jan; 144(2):153-8. PubMed ID: 1986827
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic use of gonadotropin-releasing hormone and its analogs].
Carol W
Zentralbl Gynakol; 1988; 110(12):757-65. PubMed ID: 3063027
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal therapy in metastatic prostatic cancer].
Ruffion A; Fontaine E; Staerman F
Prog Urol; 2003 Apr; 13(2):334-41. PubMed ID: 12765081
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic hormones and cancer.
Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
[TBL] [Abstract][Full Text] [Related]
16. Advanced indications for gonadotropin-releasing hormone (GnRH) analogues in gynecological oncology (review).
Sugiyama M; Imai A; Takahashi S; Hirano S; Furui T; Tamaya T
Int J Oncol; 2003 Aug; 23(2):445-52. PubMed ID: 12851694
[TBL] [Abstract][Full Text] [Related]
17. LH-RH-endocrine manipulation in cancer of the prostate.
Falcone T; Falutz G; Tolis G
Biomed Pharmacother; 1982; 36(8-9):344-8. PubMed ID: 6303470
[TBL] [Abstract][Full Text] [Related]
18. [LH-RH analogues in metastatic breast cancer: first results].
Terzoli E; Izzo F; Nisticò C; Lucatelli S; Ranuzzi M
G Ital Oncol; 1988; 8(2):59-63. PubMed ID: 3065224
[No Abstract] [Full Text] [Related]
19. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
[TBL] [Abstract][Full Text] [Related]
20. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
